Lupin launches Molnupiravir in India as ‘Molnulup’ for COVID treatment


Lupin announced the launch of Molnupiravir in India under the brand name Molnulup. This drug has been given emergency use authorization by the Drug Controller General of India (DCGI) for treatment of adult patients with Covid19, with SpO2 > 93%, and the ones who have a high risk of progression of the disease including hospitalization, company said in its release.

Lupin was quoting at Rs 923.55, up Rs 0.05, or 0.01 percent on the BSE.

News Source:- Moneycontrol

For Enquiry Fill The Form

    *Note:- Please provide a valid Email Id to receive OTP from

    Facebook Iconfacebook like buttonYouTube IconTwitter Icontwitter follow button